SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jackman DM,Johnson BE. Small-cell lung cancer. Lancet. 2005; 366: 13851396.
  • 2
    Thatcher N,Faivre-Finn C,Lorigan P. Management of small-cell lung cancer. Ann Oncol. 2005; 16( suppl 2): ii235ii239.
  • 3
    Noda K,Nishiwaki Y,Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346: 8591.
  • 4
    Hanna N,Bunn PAJr,Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006; 24: 20382043.
  • 5
    Postmus PE,Smit EF. Treatment of relapsed small cell lung cancer. Semin Oncol. 2001; 28: 4852.
  • 6
    Spiro SG,Souhami RL,Geddes DM, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer. 1989; 59: 578583.
  • 7
    O'Brien ME,Ciuleanu TE,Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006; 24: 54415447.
  • 8
    Giaccone G,Donadio M,Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988; 6: 12641270.
  • 9
    Johnson DH,Greco FA,Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol. 1990; 8: 16131617.
  • 10
    Ebi N,Kubota K,Nishiwaki Y, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol. 1997; 27: 166169.
  • 11
    Therasse P,Arbuck SG,Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 12
    Simon GR,Wagner H. Small cell lung cancer. Chest. 2003; 123: 259S271S.
  • 13
    Sundstrom S,Bremnes RM,Kaasa S, et al. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer. 2005; 48: 251261.
  • 14
    von Pawel J,Schiller JH,Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17: 658667.
  • 15
    Eckardt JR,von Pawel J,Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007; 25: 20862092.
  • 16
    Onoda S,Masuda N,Seto T, et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol. 2006; 24: 54485453.
  • 17
    Kato T,Nokihara H,Ohe Y, et al. Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2006; 24: 7061.
  • 18
    Goto K,Sekine I,Nishiwaki Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer. Br J Cancer. 2004; 91: 659665.
  • 19
    Kim Y,Goto K,Nishiwaki Y, et al. Phase II study of weekly cisplatin, etoposide and irinotecan (PE/CPT) for refractory relapsed small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2006; 24: 7088.